Transcera
- Biotech or pharma, therapeutic R&D
Transcera is pioneering targeted extracellular protein degradation using novel sphingolipid biology discovered at Harvard. Unlike receptor-mediated protein degraders, Transcera’s degraders work across diverse tissues, have extended half-life for durable target depletion, and are simple to manufacture. With a rapidly advancing pipeline of degraders for immune disorders, Transcera aims to transform the treatment landscape for chronic diseases driven by extracellular proteins. The company is backed by Digitalis Ventures, Pear VC, KdT Ventures, and Xora Innovation and is headquartered in Kendall Square, Cambridge, MA.
Address
CambridgeMassachusetts
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}